19 / 20
Page 51
Der Pharmacia Sinica
ISSN: 0976-8688
Eurosc i con Conference on
Medicinal Chemistry
and Biosimilars
M a r c h 2 5 - 2 6 , 2 0 1 9
B u d a p e s t , H u n g a r y
Medicinal Chemistry & Biosimilars 2019
R
ecurrence reduction and complete tumor eradication are critical for survival of bladder cancer patients. We have developed
novel multifunctional agents for image-guided (PET/fluorescence) photodynamic therapy (PDT) for treating bladder cancer
with low and high expression of epidermal growth factor receptor (EGFR). A photosensitizer (PS)-erlotinib conjugate recently
developed in our laboratory showed high selectivity to EGFR positive bladder cancer tumor cells (UMUC-3), with enhanced PDT
efficacy than the related non-targeted analog. We have used both active and passive approaches for improved tumor-specificity.
These results provide an opportunity to select the PS (combination with radioactive and non-radioactive analog) for imaging
bladder cancer and subsequent treatment by fluorescence-guided surgery, a see and treat approach in combination with PDT
and/or chemotherapy (U S Patent application: submitted). Depending on the stage of cancer, we propose to follow use of PDT
with intra-vesical therapy for non-muscle invasive bladder cancer (NMIBC), or as a part of multimodality bladder preservation
therapy for muscle-invasive bladder cancer (MIBC). In a parallel study, we have shown that 3D culture system derived from lung
and head/neck cancer patients helps to determine tumor-specificity of the PS and the photo-induced STAT3 dimerization can be
used as a biomarker in optimizing the PDT-treatment of bladder cancer. We expect that translating these key findings into clinical
practice will create a paradigm shift in treatment for loco-regional control of disease. Recent results from our laboratories will be
presented.
ravindra.pandey@roswellpark.orgEpidermal growth factor receptor (EGFR)
targeted multifunctional photosensitizers for
bladder cancer imaging (Fluorescence/PET) and
therapy
Ravindra K Pandey
Roswell Park Cancer Center, USA
Der Pharmacia Sinica 2019, Volume:10
DOI: 10.21767/0976-8688-C1-003